PLAINSBORO, N.J., Feb. 21, 2018 -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will present at the following healthcare conferences in March:
- On Monday, March 5, 2018 at 4:35 p.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Raymond James 39th Annual Institutional Investors Conference in Orlando, FL. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com.
- On Tuesday, March 13, 2018 at 8:30 a.m. ET, Glenn Coleman, chief financial officer and corporate vice president of International, will present at the Barclays Global Healthcare Conference in Miami Beach, FL. The session will be available through live audio webcast and can be accessed from the Investor section of www.integralife.com.
- On Wednesday, March 21, 2018 at 10:20 a.m. ET, Dan Reuvers, corporate vice president and president of Codman Specialty Surgical, will present at the Oppenheimer 28th Annual Healthcare Conference in New York City.
About Integra
Integra LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for clinicians, so they can concentrate on providing the best patient care. Integra offers innovative solutions, including leading plastic and regenerative technologies, in specialty surgical solutions, orthopedics and tissue technologies. For more information, please visit www.integralife.com
Statements made at the upcoming conferences may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals, market potential and resulting sales as well as potential therapeutic applications, and additional acquisitions. These risks and uncertainties include market conditions and other factors beyond the Company's control and the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in item 1A of Integra's Annual Report on Form 10-K for the year ended December 31, 2016 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations:
Michael Beaulieu
Director, Investor Relations
(609) 750-2827
[email protected]
Media Contact:
Laurene Isip
Senior Director, Global Corporate Communications
(609) 750-7984
[email protected]


Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins
Amazon Explores AI Content Marketplace With Media Publishers
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 



